Kestra Medical Technologies, Ltd. (KMTS)

KMTS Income Statement

Financials in millions USD. Fiscal year is May - April.

Year Ending	TTM	Apr 30, 2024	Apr 30, 2023
Revenue	45.82	27.81	7.63
Revenue Growth (YoY)	-	264.53%	-
Cost of Revenue	-	27.45	18.28
Gross Profit	12.31	0.36	-10.65
Selling, General & Admin	-	69.94	54.01
Research & Development	-	15.49	15.76
Operating Expenses	-	85.43	69.77
Operating Income	-77.86	-85.06	-80.42
Interest Expense / Income	6.86	6.23	5.63
Other Expense / Income	0.12	2.8	-1.83
Pretax Income	-93.67	-100.82	-86.72
Income Tax	0	0.02	0.02
Net Income	-84.85	-94.12	-84.24
Preferred Dividends	9.51	6.72	2.5
Net Income Common	-93.67	-100.84	-86.74
Free Cash Flow	-86.76	-84.46	-83.57
Gross Margin	26.86%	1.30%	-139.59%
Operating Margin	-169.91%	-305.83%	-1054.01%
Profit Margin	-204.41%	-362.55%	-1136.79%
Free Cash Flow Margin	-189.34%	-303.66%	-1095.27%
EBITDA	-75.13	-82.42	-75.79
EBITDA Margin	-163.95%	-296.31%	-993.34%
Depreciation & Amortization	12.37	12.17	5.3
EBIT	-87.5	-94.59	-81.09
EBIT Margin	-190.94%	-340.07%	-1062.82%

Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).